JFL Life SciencesNSE:JFLLIFE +3.59%69 WACC % is 11.49% as of Jul. 05, 2026, which is 24% above its 10-year median of 9.28. GuruFocus rates NSE:JFLLIFE with a GF Score™ of 69/100 and a GF Value™ of ₹35.70 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,017 Drug Manufacturers companies, JFL Life Sciences ranks worse than 75.02% on this metric.
As of today (2026-07-05), JFL Life Sciences's weighted average cost of capital is 11.49%%. JFL Life Sciences's ROIC % is 10.39% (calculated using TTM income statement data).
JFL Life Sciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.
For a comprehensive WACC calculation, please access the WACC Calculator.
JFL Life Sciences (NSE:JFLLIFE) WACC % Explanation
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, JFL Life Sciences's weighted average cost of capital is 11.49%%. JFL Life Sciences's ROIC % is 10.39% (calculated using TTM income statement data).
JFL Life Sciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.
2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.
3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
4. GuruFocus uses the latest annual Interest Expense divided by the latest one-year annual average debt to get the simplified cost of debt.
Related Terms
JFL Life Sciences WACC % Historical Data
* Premium members only.
The historical data trend for JFL Life Sciences's WACC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, JFL Life Sciences's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JFL Life Sciences WACC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JFL Life Sciences's WACC % distribution charts can be found below:
* The bar in red indicates where JFL Life Sciences's WACC % falls into.
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
WACC
=
E
/
(E + D)
*
Cost of Equity
+
D
/
(E + D)
*
Cost of Debt
*
(1 - Tax Rate)
1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, JFL Life Sciences's market capitalization (E) is ₹349.122 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2025, JFL Life Sciences's latest one-year annual average Book Value of Debt (D) is ₹81.4125 Mil.
a) weight of equity = E / (E + D) = 349.122 / (349.122 + 81.4125) = 0.8109
b) weight of debt = D / (E + D) = 81.4125 / (349.122 + 81.4125) = 0.1891
2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 7.02%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. JFL Life Sciences's beta is 0.8700.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 7.02% + 0.8700 * 6% = 12.24%
3. Cost of Debt:
GuruFocus uses latest annual Interest Expense divided by the latest one-year annual average debt to get the simplified cost of debt.
As of Mar. 2025, JFL Life Sciences's interest expense (positive number) was ₹9.928 Mil. Its total Book Value of Debt (D) is ₹81.4125 Mil.
Cost of Debt = 9.928 / 81.4125 = 12.1947%.
4. Multiply by one minus annual Tax Rate:
GuruFocus uses the most recent annual Tax Expense divided by the most recent annual Pre-Tax Income to calculate the tax rate. The calculated annual tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated annual Tax Rate = 19.769 / 61.354 = 32.22%.
JFL Life Sciences's Weighted Average Cost Of Capital (WACC) for Today is calculated as:
WACC
=
E / (E + D)
*
Cost of Equity
+
D / (E + D)
*
Cost of Debt
*
(1 - Tax Rate)
=
0.8109
*
12.24%
+
0.1891
*
12.1947%
*
(1 - 32.22%)
=
11.49%
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JFL Life Sciences (NSE:JFLLIFE) has a WACC % of 11.49% as of Jul. 05, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on JFL Life Sciences and its competitors. This is 24% above median its historical median of 9.28. Over the past decade, JFL Life Sciences' WACC % has ranged from 5.36 to 12.68. According to the industry distribution chart, JFL Life Sciences ranks #763 out of 1017 companies in the Drug Manufacturers industry, placing it in the top 75%.
Is JFL Life Sciences' WACC % too high?
JFL Life Sciences' current WACC % of 11.49% is 24% above median its 10-year median of 9.28. Over the past 10 years, this metric has ranged from a low of 5.36 to a high of 12.68. The Drug Manufacturers industry median WACC % is 8.95. JFL Life Sciences' value of 11.49% is 28.4% above this industry median. Based on the distribution chart, JFL Life Sciences ranks #763 out of 1017 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, JFL Life Sciences has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JFL Life Sciences' WACC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, JFL Life Sciences ranks #763 out of 1017 companies for WACC %. This places JFL Life Sciences in the lower half of its industry. The industry median WACC % is 8.95. JFL Life Sciences' value of 11.49% is 28.4% above this benchmark. Historically, JFL Life Sciences' own WACC % has ranged from 5.36 to 12.68 over the past decade. While the company's 10-year median is 9.28 vs. the industry median of 8.95, JFL Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Drug Manufacturers company?
The median WACC % among Drug Manufacturers companies is 8.95, based on 1,017 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JFL Life Sciences's current WACC % of 11.49% is 28.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on JFL Life Sciences and its competitors. For the Drug Manufacturers industry, the median WACC % is 8.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JFL Life Sciences's current WACC % is 11.49%, which is 24% above median its own 10-year median of 9.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JFL Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, JFL Life Sciences (NSE:JFLLIFE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹35.70, compared to a current price of ₹10.10 — trading 71.7% below its estimated fair value. The current WACC % is 11.49%, which is 24% above median its 10-year median of 9.28 and 28.4% above the Drug Manufacturers industry median of 8.95. JFL Life Sciences' overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For JFL Life Sciences (NSE:JFLLIFE), the current WACC % is 11.49% as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JFL Life Sciences (NSE:JFLLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, JFL Life Sciences stock appears to be undervalued.
The current stock price of ₹10.10 is trading 71.7% below its estimated GF Value™ of ₹35.70.
GuruFocus considers JFL Life Sciences to be Significantly Undervalued.
Key valuation signals for NSE:JFLLIFE:
WACC %: 11.49% (24% above median its 10-year median of 9.28)
GF Value™: ₹35.70 vs. price of ₹10.10 (71.7% below fair value)
Industry Position: 28.4% above the Drug Manufacturers median (#763 of 1017)
No single metric tells the full story. See the NSE:JFLLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
69GF Score
Get the complete analysis for NSE:JFLLIFE
WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JFLLIFE has been successfully added to your 